New combo therapy offers hope for tough breast cancers

This study tests whether adding the immunotherapy drug toripalimab and targeted radiation to standard chemotherapy can help shrink HER2-negative breast tumors that didn't respond to initial chemo. About 110 adults with early-stage breast cancer will be split into groups receiving chemo alone, chemo plus toripalimab, or all three treatments before surgery. The goal is to see if the combination leads to no cancer remaining at surgery, and participants who get toripalimab will continue it after surgery for about a year.